Cowen Pounds the Table on Horizon Therapeutics (HZNP), Says Add to Positions Before Earnings

July 21, 2021 8:49 AM EDT
Get Alerts HZNP Hot Sheet
Price: $108.80 +0.79%

Rating Summary:
    15 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 7 | Down: 15 | New: 24
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Cowen analyst Ken Cacciatore reiterated an Outperform rating and $120.00 price target on Horizon Therapeutics (NASDAQ: HZNP) expecting the company to exceed the Street Consensus on Q2 revenue/earnings, on the strength of Tepezza, given the patient metrics and consultants' commentary.

The analyst stated "we believe HZNP will not only beat the Street's $325MM Tepezza est, butwill also correspondingly increase the full-year guidance now that it has a better handle onthe Tepezza relaunch cadence and trajectory." He went on to comment "our mid-quarterTepezza consulting checks on the relaunch could not have been more encouraging".

For an analyst ratings summary and ratings history on Horizon Therapeutics click here. For more ratings news on Horizon Therapeutics click here.

Shares of Horizon Therapeutics closed at $94.23 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot Comments

Related Entities

Cowen & Co, Earnings